Eikonoklastes Therapeutics
Bruce Halpryn is the Co-Founder & CEO at Eikonoklastes Therapeutics. He is also a Board member, former chair of artistic and marketing committees at Cincinnati Ballet, Board of Trustees.
Eikonoklastes Therapeutics
1 followers
Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment.